GlassScriptPhysician profile
Garrett D White
NPI 1225031842
$9,676.39
in general payments reported to CMS, 2019-2025
40 companies · $2,258 in 2025
The $2,258 reported for 2025 was more than what 90% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $830 · 2020: $650 · 2021: $1,056 · 2022: $1,107 · 2023: $1,890 · 2024: $1,886 · 2025: $2,258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,400 · Education: $634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,400.05 |
| Education | $633.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,175.22 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $1,107.70 | 2019-2025 | Krystexxa, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $941.88 | 2019-2025 | Jynarque, Voyxact |
| Opko Pharmaceuticals, LLC | $831.18 | 2019-2025 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $778.87 | 2020-2025 | Acthar |
| Vifor Pharma, INC. | $670.75 | 2020-2025 | Veltassa |
| Novartis Pharmaceuticals Corporation | $663.97 | 2019-2025 | |
| Travere Therapeutics, INC. | $547.23 | 2019-2025 | Filspari |
| Bayer Healthcare Pharmaceuticals INC. | $509.18 | 2021-2025 | |
| Calliditas Therapeutics US INC. | $391.13 | 2022-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $258.19 | 2021-2025 | Lupkynis |
| Ardelyx, INC. | $248.23 | 2024-2025 | Ibsrela |
| Novo Nordisk INC | $237.43 | 2023-2025 | Ozempic, Rybelsus |
| Alnylam Pharmaceuticals INC. | $206.89 | 2024-2025 | Onpattro, Amvuttra |
| Medtronic, INC. | $159.57 | 2023 | Onyx Frontier |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garrett White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.